ARS Pharmaceuticals (SPRY) Total Non-Current Liabilities (2021 - 2026)

ARS Pharmaceuticals (SPRY) has 5 years of Total Non-Current Liabilities data on file, last reported at $221.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $221.8 million; the trailing twelve-month figure through Mar 2026 stood at $221.8 million (changed N/A YoY), and the FY2025 full-year result was $208.8 million, up 121.28% from the prior year.
• Total Non-Current Liabilities grew to $221.8 million in Q1 2026, from $208.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $221.8 million in Q1 2026 to a low of $8.5 million in Q4 2022.
• A 4-year average of $145.8 million and a median of $164.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities plunged 48.48% in 2022 and surged 121.28% in 2025, its largest moves.
• Tracing SPRY's Total Non-Current Liabilities over 4 years: stood at $8.5 million in 2022, then jumped by 1003.7% to $94.4 million in 2024, then jumped by 121.28% to $208.8 million in 2025, then grew by 6.22% to $221.8 million in 2026.
• Business Quant data shows SPRY's Total Non-Current Liabilities at $221.8 million in Q1 2026, $208.8 million in Q4 2025, and $221.4 million in Q3 2025.